The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NUMI | -65.52% | -86.84% | -29.6% | -95% |
| S&P | +15.37% | +82.64% | +12.79% | +128% |
Numinus Wellness, Inc engages in the development of psychedelic-centered therapeutic products and services. It operates through the following segments: Numinus Bioscience, Numinus Health, Mindspace, and Corporate. The Numinus Bioscience segment extracts natural Psilocybe and other psychoactive fungi species, and develops proprietary processes and products. The Numinus Health segment offers the therapeutic use of psychedelics in accordance with regulatory approvals to deliver additional health and wellness solutions to the market. The Mindspace segment provides clinic services with a focus evidence-based approaches to mental health, which delivers health and wellness solutions to the Quebec market. The company was founded on June 26, 1962 and is headquartered in Vancouver, Canada.
No news articles found for Numinus Wellness.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.80M | -58.5% |
| Gross Profit | $780.99K | 16.8% |
| Gross Margin | 43.32% | 27.9% |
| Market Cap | $16.32M | -7.2% |
| Net Income | -$668.81K | 86.9% |
| EBITDA | -$509.56K | 85.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $822.84K | -77.8% |
| Accounts Receivable | $1.42M | -16.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.73M | -60.7% |
| Short Term Debt | $589.42K | -77.8% |
| Q2 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -105.85% | 0.0% |
| Return On Invested Capital | -146.59% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $392.99K | 111.3% |
| Operating Free Cash Flow | $390.09K | 111.3% |
| Metric | Q2 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.50 | 3.81 | 3.46 | 3.46 | -9.29% |
| Price to Sales | 1.37 | 0.81 | - | ||
| Price to Tangible Book Value | 4.50 | 3.81 | 3.46 | 3.46 | -9.28% |
| Enterprise Value to EBITDA | -5.85 | -21.18 | -8.29 | -27.72 | 291.61% |
| Return on Equity | -136.5% | -182.9% | - | ||
| Total Debt | $7.08M | $2.46M | $2.54M | $2.32M | -63.59% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
